Results: 8
Sparsentan: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 6, p. 563, doi. 10.1007/s40265-023-01864-x
- By:
- Publication type:
- Article
Elacestrant: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 6, p. 555, doi. 10.1007/s40265-023-01861-0
- By:
- Publication type:
- Article
Pirtobrutinib: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 6, p. 547, doi. 10.1007/s40265-023-01860-1
- By:
- Publication type:
- Article
Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms.
- Published in:
- Drugs, 2023, v. 83, n. 6, p. 497, doi. 10.1007/s40265-023-01857-w
- By:
- Publication type:
- Article
Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline.
- Published in:
- Drugs, 2023, v. 83, n. 6, p. 479, doi. 10.1007/s40265-023-01856-x
- By:
- Publication type:
- Article
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy.
- Published in:
- Drugs, 2023, v. 83, n. 6, p. 507, doi. 10.1007/s40265-023-01855-y
- By:
- Publication type:
- Article
Effectiveness of Nutritional Therapies in Male Factor Infertility Treatment: A Systematic Review and Network Meta-analysis.
- Published in:
- Drugs, 2023, v. 83, n. 6, p. 531, doi. 10.1007/s40265-023-01853-0
- By:
- Publication type:
- Article
Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?
- Published in:
- Drugs, 2023, v. 83, n. 6, p. 469, doi. 10.1007/s40265-023-01852-1
- By:
- Publication type:
- Article